ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,135,381 | +290.7% | 31,848 | +405.5% | 0.00% | – |
| Q2 2023 | $290,619 | +6.3% | 6,300 | +6.8% | 0.00% | -100.0% |
| Q4 2022 | $273,347 | -38.3% | 5,900 | -44.9% | 0.00% | 0.0% |
| Q3 2022 | $443,000 | -63.1% | 10,700 | -46.8% | 0.00% | -75.0% |
| Q2 2022 | $1,199,000 | -76.7% | 20,100 | -71.6% | 0.00% | -75.0% |
| Q1 2022 | $5,135,000 | +104.0% | 70,705 | +136.3% | 0.02% | +100.0% |
| Q4 2021 | $2,517,000 | +67.0% | 29,923 | +126.1% | 0.01% | +14.3% |
| Q1 2021 | $1,507,000 | -43.5% | 13,233 | -31.3% | 0.01% | -36.4% |
| Q4 2020 | $2,665,000 | +542.2% | 19,249 | +263.2% | 0.01% | +266.7% |
| Q2 2020 | $415,000 | -67.7% | 5,300 | -71.4% | 0.00% | -70.0% |
| Q1 2019 | $1,283,000 | +5245.8% | 18,500 | +8464.8% | 0.01% | – |
| Q4 2015 | $24,000 | +140.0% | 216 | +116.0% | 0.00% | – |
| Q3 2015 | $10,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |